Curated News
By: NewsRamp Editorial Staff
June 24, 2026
Hong Kong's Largest Biotech Delegation Heads to BIO 2026
TLDR
- HKSTP leads 41 Hong Kong biotech firms to BIO 2026, doubling presence and forging global partnerships to gain market advantage.
- HKSTP's delegation signs MOUs with LabCentral, Immuno Cure, and Zhaoke Ophthalmology to advance cross-border clinical trials and commercialization.
- Hong Kong biotech delegation aims to accelerate life-changing healthcare solutions, improving global health outcomes through international collaboration.
- HKSTP park company Meta Pharmaceuticals won third place at a biomedical pitch competition in Boston, showcasing next-gen autoimmune therapeutics.
Impact - Why it Matters
This news matters because Hong Kong's expanded presence at BIO 2026 signals its growing influence as a global biotech hub, enabling local innovators to secure international partnerships and funding. For patients worldwide, these collaborations could accelerate access to groundbreaking treatments in areas like HIV, ophthalmology, and autoimmune diseases. The delegation's success also highlights the importance of cross-border innovation in tackling global health challenges, potentially driving economic growth and job creation in the life sciences sector.
Summary
Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, the Hong Kong Trade Development Council (HKTDC), and five top universities, has led the city's largest-ever delegation of life and health technology innovators to the BIO International Convention 2026 (BIO 2026) in San Diego. The delegation, doubling the size of last year's Hong Kong Pavilion, includes 41 organizations from HKSTP, partner companies, research institutes, and university spin-offs. This landmark presence showcases Hong Kong's strengths in AI-enabled biotech, therapeutics, diagnostics, and pharma innovation, with potential “First-in-Class” and “Best-in-Class” assets. The city aims to reinforce its status as Asia's largest and the world's second largest fundraising hub for biotechnology.
Key highlights include three major strategic partnerships signed at BIO 2026. HKSTP signed an MOU with LabCentral, one of the largest global non-profit biotech incubators, to deepen ties between U.S. and Hong Kong life sciences ecosystems. Immuno Cure, developer of a first-in-human therapeutic HIV vaccine ICVAX, announced collaboration with OPIS, an international Contract Research Organization, to support overseas clinical trials and global expansion. Zhaoke Ophthalmology signed an MOU with Laboratório Teuto, Brazil's first generic medicine producer, to explore cross-border cooperation in ophthalmology, marking its first strategic MOU in the Brazilian market. Additionally, HKSTP CEO Terry Wong participated in a panel sharing session on translating innovation across borders, and the delegation visited the Salk Institute to explore partnerships. A Global Mixer was hosted with industry leaders and venture capital firms, including Bayer Pharmaceuticals, Johnson & Johnson Innovation, LabCentral, Roche, Simcere Pharmaceutical, and T.Rx Capital.
Beyond the convention, HKSTP co-organized the 2026 Biomedical Pitch Competition in Boston, where park company Meta Pharmaceuticals (HK) Limited won Third Place for its next-generation autoimmune therapeutics. This recognition underscores the strength of Hong Kong's biotech pipeline. As the city's innovation ecosystem orchestrator, HKSTP is home to over 300 life and health technology companies and continues to empower innovators, bridging global opportunities with Asia. The delegation reinforces Hong Kong's role as a super-connector in the global healthcare market, leveraging world-class universities and strong R&D capabilities to translate breakthroughs into life-changing solutions.
Source Statement
This curated news summary relied on content disributed by Media Outreach. Read the original source here, Hong Kong's Largest Biotech Delegation Heads to BIO 2026
